Westbourne Investment Advisors Inc. Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Westbourne Investment Advisors Inc. lowered its holdings in Bristol-Myers Squibb (NYSE:BMY) by 8.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,477 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Westbourne Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $253,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. AMF Tjanstepension AB boosted its position in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after purchasing an additional 39,419 shares during the period. Atomi Financial Group Inc. acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $371,000. CWM LLC boosted its stake in Bristol-Myers Squibb by 7.1% during the 3rd quarter. CWM LLC now owns 581,448 shares of the biopharmaceutical company’s stock worth $30,084,000 after purchasing an additional 38,761 shares during the period. Wedmont Private Capital grew its position in Bristol-Myers Squibb by 14.1% during the 3rd quarter. Wedmont Private Capital now owns 8,095 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 999 shares during the last quarter. Finally, Sanibel Captiva Trust Company Inc. increased its stake in Bristol-Myers Squibb by 47.1% in the third quarter. Sanibel Captiva Trust Company Inc. now owns 35,320 shares of the biopharmaceutical company’s stock valued at $1,827,000 after purchasing an additional 11,315 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a report on Tuesday, November 12th. Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Truist Financial upped their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Morgan Stanley boosted their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Finally, Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Down 0.8 %

BMY stock opened at $56.96 on Friday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The company’s 50 day simple moving average is $57.61 and its 200-day simple moving average is $53.65. The firm has a market capitalization of $115.51 billion, a PE ratio of -15.86, a P/E/G ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. Equities analysts expect that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.35%. Bristol-Myers Squibb’s payout ratio is -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.